The Supply Chain Status in China

As of September 30, 2024, there are 29 potential suppliers manufacturing Elacestrant intermediate N-ethyl-2-(4-formylphenyl)acetamide (CAS No. 2477812-42-1), including 19 factories, among which:

- The 25th percentile has an average registered capital of 1 million CNY;

- The 50th percentile has an average registerd capital of 4 million CNY;

- The 75th percentile has an average registered capital of 10.19 million CNY.

The Demand

We estimate the demand ceiling for this Elacestrant intermediate N-ethyl-2-(4-formylphenyl)acetamide (CAS No. 2477812-42-1) is:
- Global: 4.645 tons

- US: 0.668 tons

- Europe: 1.164 tons

Feeling overwhelmed? Contact Unibest if you need us to quality-check other sources to strengthen your supply chain or to find a tailored solution for your specific procurement request.

Unibest's Elacestrant Project Experience

From 2023, Unibest has partnered with our CDMO partner to develop Elacestrant intermediates for out Europe and India generic pharmaceutical clients. 

For this Elacestrant intermediate N-Ethyl-2-(4-formylphenyl)acetamide, CAS No. 2477812-42-1, our CDMO partner has planned 100~300 kg annual production capacity, and we are able to raise it to tons.

Structure of Elacestrant

Elacestrant API is featured with a chiral center. Elacestrant structure is formed by reacting with amine and aldehyde groups.

The Overall Synthesis of Elacestrant API

There are two essential routes leading to the syntehsis of Elacestrant API. One is from the innovator Radius Pharmaceuticals (lower part of the Elacestrant ROS map) and from a generic-CDMO route. 

The Elacestrant intermediate N-Ethyl-2-(4-formylphenyl)acetamide, CAS No. 2477812-42-1, is the achiral moiety that feed into the innovator route. The aldehyde group reacts with the amine group from the chiral moiety (CAS No. 2477812-39-6), and forms the N-1 Elacestrant intermediate, which requires further reduction of the ketone group.

Reference

Legoabe, L. J., Petzer, A. & Petzer, J. P. α-Tetralone derivatives as inhibitors of monoamine oxidase. Bioorganic & Medicinal Chemistry Letters 24, 2758–2763 (2014).

Sun, S., Ye, J., Zhao, L., Hu, C. & Chen, Z. Triazolotriazine Derivatives as A2a Receptor Antagonists. (2020).

Kobayashi, S. et al. Sulfonyl derivatives. (2003).

Kobayashi, S. et al. Sulfonyl derivatives. (2003).

Aguilar, N., Fernandez, J. C., Terricabras, E., Carceller, G. E. & Salas, S. J. Substituted Tricyclic Compounds with Activity Towards Ep1 Receptors. (2013).

Yan, W. et al. Structure-Based Design of Dual-Acting Compounds Targeting Adenosine A2A Receptor and Histone Deacetylase as Novel Tumor Immunotherapeutic Agents. J. Med. Chem. 64, 16573–16597 (2021).

Molander, G. A. & Jean-Gérard, L. Scope of the Suzuki−Miyaura Aminoethylation Reaction Using Organotrifluoroborates. J. Org. Chem. 72, 8422–8426 (2007).

Markey, M. Processes and Compounds. (2020).

Sturdivant, J. M., Delong, M. a, Chambournier, G., Pamment, M. G. & Fedij, V. Process for the preparation of kinase inhibitors and intermediates thereof. (2017).

Wang, T. et al. Preparation method of N-ethyl-2-(4-formylphenyl) acetamide. (2023).

Cheng, G. Preparation method of intermediate of medicine for treating advanced breast cancer. (2023).

Huang, Z., Qiu, B., Zhong, B. & Zhang, J. Preparation method of ilastrant intermediate (R)-6-(2-amino-4-methoxyphenyl)-5, 6, 7, 8-tetrahydronaphthalene-2-alcohol. (2024).

Fu, Q. et al. Preparation method of ilastrant intermediate. (2023).

Wang, T., Zhu, Y., Yuan, S., Liu, H. & Wang, J. Preparation method of Alalisset. (2023).

Hong, H., Zhang, E., Liu, Z., Xiao, Y. & Hou, H. Photocatalytic continuous bromination method. (2021).

Madden, J., Hallett, D. J., Parkes, A., Raoof, A. & Wang, X. New Bradykinin B1 Antagonists. (2010).

Miyaji, R., Asano, K. & Matsubara, S. Induction of Axial Chirality in 8‐Arylquinolines through Halogenation Reactions Using Bifunctional Organocatalysts. Chemistry A European J 23, 9996–10000 (2017).

Caldwell, R. D. et al. Heterobicyclic sphingosine 1-phosphate analogs. (2014).

Amberg, W. et al. Fused (hetero)cyclic Compounds as S1p Modulators. (2017).

Ward, R. A. et al. Design and Synthesis of Novel Lactate Dehydrogenase A Inhibitors by Fragment-Based Lead Generation. J. Med. Chem. 55, 3285–3306 (2012).

Clark, M. P., Lockwood, M. a, Wagner, F. F. & Natchus, M. G. Chemokine Receptor Modulators. (2008).

Zhang, W., Chu, D., Yuan, Q. & Xie, X. Asymmetric catalytic hydrogenation process for cyclohexene derivatives. (2024).

Almansa, C., Carceller, E., Bartrolí, J. & Forn, J. A Short, Efficient Synthesis of 6-Cyano-1-tetralones. Synthetic Communications (1993) doi:10.1080/00397919308011138.